CLL/SLL

William Wierda | ASCO 2018 | Ibrutinib and venetoclax combination for first-line CLL: CAPTIVATE phase II trial

L:

ASCO Annual Meeting, 1-5 June 2018, Chicago, IL

William Wierda
MD Anderson Cancer Center, Houston, US

Interview topic: Ibrutinib and venetoclax combination for first-line CLL: the CAPTIVATE phase II trial

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF